Clinical Documents

To edit the draft, click on the text box below.

×

Draft a comprehensive differential diagnosis for acute substernal chest pain in a 45-year-old male with hypertension and hyperlipidemia, diaphoresis, exertional onset, and normal initial ECG/troponin; include life-threatening causes first, key distinguishing features, and immediate diagnostic next steps.

Draft a detailed differential diagnosis for new-onset unilateral throbbing headache with visual aura and brief monocular vision loss in a 32-year-old female on oral contraceptives; include red-flag symptoms, stroke/TIA considerations, and recommended initial workup.

Draft an assessment and plan for stage-2 hypertension (BP 162/98) in an obese 52-year-old with suspected obstructive sleep apnea; include ASCVD risk estimate, lifestyle prescriptions, first-line pharmacotherapy with drug/dose/targets, baseline labs/monitoring, and 4–6 week follow-up.

Draft an assessment and plan for type 2 diabetes follow-up with A1c 9.2% on metformin 1,000 mg BID and eGFR 65; compare adding a GLP-1 receptor agonist vs an SGLT2 inhibitor, address weight loss goals, hypoglycemia education, vaccinations, and micro/macrovascular screening.

Draft a history and physical for a patient presenting with chest pain, including HPI using OLDCARTS, pertinent ROS, PMH/meds/allergies, FH/SH, focused cardiac/pulmonary exam, initial labs and imaging orders, prioritized differential, HEART score risk stratification, and early management.

Draft a history and physical for a new patient with progressive exertional dyspnea, orthopnea, and bilateral leg edema; include differential (heart failure, COPD, PE, anemia, renal disease), targeted exam maneuvers, and first-line diagnostics and management.

Draft a progress note for COPD follow-up two weeks after an acute exacerbation treated with prednisone and antibiotics; include symptom trajectory, CAT score (if available), inhaler technique/adherence, oxygen needs, spirometry plan, smoking cessation counseling, and return precautions.

Draft a progress note for post-operative day 2 after total knee arthroplasty; include pain control strategy, DVT prophylaxis, PT/OT milestones, wound status, bowel/urinary function, labs/vitals review, complications screening, and discharge readiness.

Draft a discharge summary for community-acquired pneumonia admission; include admission/discharge dates, presenting symptoms, radiology/labs, pathogen if identified, inpatient therapies and response, discharge medications with durations, pending tests, follow-up appointments, and return precautions.

Draft a discharge summary for myocardial infarction managed with PCI and drug-eluting stent placement; include cath findings, complications, inpatient course, discharge medications (DAPT, statin, beta-blocker, ACEi/ARB), cardiac rehab referral, and follow-up plan.

Draft discharge instructions for a patient hospitalized with acute decompensated heart failure; include daily weights, sodium and fluid restriction amounts, medication list with dosing, signs of worsening heart failure, follow-up appointments, and lab monitoring plan.

Draft discharge instructions for an asthma exacerbation; include controller and reliever regimen, steroid taper schedule, spacer technique, trigger avoidance, a written asthma action plan, return precautions, and follow-up timing.

Draft a patient handout on managing high blood pressure in plain language; explain what BP numbers mean, key lifestyle steps (DASH diet, sodium limits, alcohol moderation), home BP monitoring instructions, medication adherence tips, and when to call the doctor.

Draft a patient handout for type 2 diabetes education in plain language; cover A1c goals, the plate method, physical activity targets, self-monitoring of blood glucose, hypoglycemia signs and the 15-15 rule, foot care basics, and a vaccination checklist.

Draft a summary of the latest CDC and WHO guidelines for managing community-acquired pneumonia in adults, including empiric antibiotic choices, duration of therapy, and follow-up recommendations.

Draft a plain-language overview of the ADA and AACE guidelines for diabetes management, focusing on A1c goals, weight management, and the use of GLP-1 receptor agonists and SGLT2 inhibitors.

Draft a summary of the 2024 USPSTF breast cancer screening recommendations, including updated screening intervals, risk-based approaches, and the role of MRI for high-risk patients.

Draft a concise summary of NCCN guidelines for melanoma management, including staging, surgical margins, adjuvant therapy, and checkpoint inhibitor recommendations.

Draft treatment alternatives for community-acquired MRSA skin infections in patients allergic to sulfa drugs; include oral and IV options, dosing, and duration.

Draft treatment alternatives for patients with type 2 diabetes who are unable to tolerate GLP-1 receptor agonists due to nausea; include medication substitutions and lifestyle recommendations.

Draft a summary of options for treating refractory depression, comparing ketamine infusions, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT).

Draft treatment options for advanced prostate cancer, including hormonal therapy, radiopharmaceuticals, and novel androgen receptor pathway inhibitors.

Draft a summary of recent research on mRNA vaccine technology beyond COVID-19, including applications in oncology and autoimmune disease prevention.

Draft an easy-to-understand overview of long COVID research, summarizing major symptoms, hypothesized mechanisms, and emerging treatment approaches.

Draft a summary of current research on Alzheimer’s disease biomarkers, including amyloid and tau imaging, and discuss how they influence diagnosis and trial design.

Draft an explanation of the interaction between warfarin and antibiotics such as ciprofloxacin or TMP-SMX, including INR effects and management recommendations.

Draft a summary evaluating drug interactions for patients taking Paxlovid and common cardiovascular drugs; include mechanism and recommended dose adjustments.

Draft a summary of the common and serious side effects of semaglutide, including GI intolerance, gallbladder disease, and thyroid-related warnings.

Draft an overview of potential side effects associated with long-term corticosteroid use, including osteoporosis, glucose intolerance, and adrenal suppression.

Draft a summary of essential lab tests to order in suspected acute pancreatitis, including amylase, lipase, liver enzymes, and metabolic panels, with interpretation guidance.

Draft laboratory workup recommendations for suspected hypothyroidism, including TSH, free T4, thyroid antibodies, and when to consider secondary causes.

Draft an explanation of which labs should be monitored in patients receiving methotrexate therapy, including CBC, LFTs, renal function, and frequency of monitoring.

why choose us

Edit Geo

×

300×250 Ad Slot

Research Article: Unveiling a J-shaped association between the triglyceride-glucose index and in-hospital major adverse cardiovascular events in patients with acute myocardial infarction: a retrospective cohort study of 1,065 patients

Date Published: 2026-07-07

Abstract:
This study was designed to investigate the dose-response relationship between the triglyceride-glucose (TyG) index and the occurrence of in-hospital major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI), and to examine whether a nonlinear association pattern exists. This single-center retrospective cohort study consecutively enrolled 1,065 patients diagnosed with type 1 AMI who underwent coronary angiography at the Department of Cardiology, The Second Affiliated Hospital of Shenyang Medical College, between June 2022 and June 2025. Baseline data were collected from the electronic medical record system, and the TyG index was calculated using the formula: TyG?=?Ln [triglycerides (mg/dL)?×?fasting plasma glucose (mg/dL)]/2. The primary outcome was in-hospital MACE (occurring during hospitalization, ?7 days after admission), which was a composite of all-cause mortality, acute heart failure, malignant arrhythmia, recurrent myocardial infarction, and cardiogenic shock. Patients were categorized into three groups [T1 [low], T2 [medium], and T3 [high]] based on the overall tertiles of the TyG index. Multivariable logistic regression analysis was employed to construct hierarchical models (a base model, a parsimonious model, and a core model) and to analyze the association between TyG index groups and MACE. Model performance was evaluated by assessing discrimination (area under the curve, AUC), calibration, and clinical utility. Restricted cubic splines (RCS) were used to explore the potential nonlinear relationship between the TyG index (as a continuous variable) and MACE. The inflection point was identified, and piecewise regression analysis was performed. Subgroup analyses were conducted to assess the heterogeneity of the association. This study included 1,065 patients with AMI, who were stratified into T1 (low, n =?352), T2 (medium, n =?361), and T3 (high, n =?352) groups based on TyG index tertiles. Baseline analysis revealed significant differences among the three groups in body mass index (BMI), left ventricular ejection fraction (LVEF), age, diastolic blood pressure (DBP), heart rate (HR), fasting plasma glucose (FPG), serum creatinine (Scr), lipid profiles (total cholesterol [TC], triglycerides [TG], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C]), peak cardiac troponin T (cTnT), peak N-terminal pro-B-type natriuretic peptide (NT-proBNP), prevalence of diabetes, and usage rates of angiotensin system inhibitors (ACEI/ARB/ARNI) and beta-blockers (all p <?0.05). The overall incidence of in-hospital MACE was 21.13%. Notably, the T2 group exhibited a significantly higher incidence (26.04%) compared to the T1 group (16.76%, p =?0.011). In the core multivariable logistic regression model (adjusted for age, sex, BMI, LVEF, diabetes, cTnT, NT-proBNP, etc.), the T2 group was associated with a 178% significantly increased risk of in-hospital MACE compared to the T1 group [odds ratio [OR]?=?2.78, 95% confidence interval [CI]: 1.38–5.59, p =?0.004]. The core model incorporating the TyG index groups demonstrated the best predictive performance [area under the receiver operating characteristic curve (AUC)?=?0.79, 95% CI: 0.75–0.83], good calibration (Hosmer-Lemeshow test p =?0.883), and was confirmed to provide clinical net benefit by decision curve analysis. Restricted cubic spline analysis revealed a significant J-shaped relationship between the TyG index and the risk of in-hospital MACE, with an inflection point identified at TyG?=?9.05. Piecewise regression analysis demonstrated that when the TyG index was <9.05, the MACE risk did not change significantly (OR?=?1.04, 95% CI: 0.62–1.77, P =?0.875); however, for every 1-unit increase in the TyG index???9.05, the MACE risk significantly increased by 124% (OR?=?2.24, 95% CI: 1.26–3.96, P =?0.006). Subgroup analyses (stratified by sex, smoking status, hypertension, diabetes, age, and BMI) revealed no significant heterogeneity in the association between the TyG index (?inflection point vs. ?0.05), supporting the consistency of this J-shaped association across the studied population subgroups. This study demonstrates a significant J-shaped nonlinear association between the TyG index and the risk of in-hospital MACE, with an identified inflection point at 9.05. Notably, patients with a medium TyG level (T2 group) exhibited the highest MACE risk, which was significantly greater than that of patients with a low TyG level (T1 group). This finding challenges the conventional linear perception that a higher TyG index consistently correlates with greater risk. The core model incorporating TyG index stratification significantly improved the predictive performance for MACE. These findings collectively underscore the importance of considering the nonlinear effect of the TyG index in risk assessment for AMI patients, suggesting that individuals with medium TyG levels may represent a specific high-risk subgroup warranting particular attention.

Introduction:
Acute Myocardial Infarction (AMI), a severe manifestation of Coronary Artery Disease (CAD), remains a leading cause of mortality and disability worldwide ( 1 ). Despite significant improvements in patient outcomes achieved through Percutaneous Coronary Intervention (PCI) and guideline-directed medical therapy, in-hospital Major Adverse Cardiovascular Events (MACE), including recurrent myocardial infarction, worsening heart failure, malignant arrhythmias, and cardiac death, continue to pose a serious threat to…

Read more

300×250 Ad Slot

×
Chat & Ask Questions Career Openings Medical Doctors Check on Drug
Interactions Latest Health News
by WebHealthNetwork Get CME Credits Latest Clinical Trials Latest Research Articles Clinical Documents Update Profile

News

Chat

HCP Tools

Careers

Update Profile